Literature DB >> 10096255

6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.

D J Edwards1, M E Fitzsimmons, E G Schuetz, K Yasuda, M P Ducharme, L H Warbasse, P M Woster, J D Schuetz, P Watkins.   

Abstract

BACKGROUND: 6',7'-Dihydroxybergamottin is a furanocoumarin that inhibits CYP3A4 and is found in grapefruit juice and Seville orange juice. Grapefruit juice increases the oral bioavailability of many CYP3A4 substrates, including cyclosporine (INN, ciclosporin), but intestinal P-glycoprotein may be a more important determinant of cyclosporine availability.
OBJECTIVES: To evaluate the contribution of 6',7'-dihydroxybergamottin to the effects of grapefruit juice on cyclosporine disposition and to assess the role of CYP3A4 versus P-glycoprotein in this interaction.
METHODS: The disposition of oral cyclosporine was compared in healthy subjects after ingestion of water, grapefruit juice, and Seville orange juice. Enterocyte concentrations of CYP3A4 were measured in 2 individuals before and after treatment with Seville orange juice. The effect of 6',7'-dihydroxybergamottin on P-glycoprotein was assessed in vitro.
RESULTS: Area under the whole blood concentration-time curve and peak concentration of cyclosporine were increased by 55% and 35%, respectively, with grapefruit juice (P < .05). Seville orange juice had no influence on cyclosporine disposition but reduced enterocyte concentrations of CYP3A4 by an average of 40%. 6',7'-Dihydroxybergamottin did not inhibit P-glycoprotein at concentrations up to 50 micromol/L.
CONCLUSIONS: 6',7'-Dihydroxybergamottin is not responsible for the effects of grapefruit juice on cyclosporine. Because the interaction did not occur with Seville orange juice despite reduced enterocyte concentrations of CYP3A4, inhibition of P-glycoprotein activity by other compounds in grapefruit juice may be responsible. Reduced enterocyte CYP3A4 by 6',7'-dihydroxybergamottin could be important for other drugs whose bioavailability is less dependent on P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096255     DOI: 10.1016/S0009-9236(99)70102-5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  36 in total

1.  Interaction between grapefruit juice and praziquantel in humans.

Authors:  Nelly Castro; Helgi Jung; Roberto Medina; Dinora González-Esquivel; Mario Lopez; Julio Sotelo
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Effect of grapefruit juice on the disposition of omeprazole.

Authors:  S Mouly; M F Paine
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

4.  Grapefruit juice: potential drug interactions.

Authors:  James Maskalyk
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

Review 5.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

7.  S-ketamine concentrations are greatly increased by grapefruit juice.

Authors:  Marko A Peltoniemi; Teijo I Saari; Nora M Hagelberg; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

8.  The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

Authors:  Tanja Busk Bidstrup; Per Damkier; Anette Kristensen Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 9.  Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Authors:  Lilian W Kibathi; SoHyun Bae; Scott R Penzak; Parag Kumar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

Review 10.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.